A(1) or A(3) adenosine receptors induce late preconditioning against infarction in conscious rabbits by different mechanisms.
We investigated whether activation of A(1) or A(3) adenosine receptors (ARs) induces late preconditioning (PC) against infarction in conscious rabbits using the selective AR agonists 2-chloro-N(6)-cyclopentyladenosine (CCPA) and N(6)-3-iodobenzyladenosine-5'-N-methylcarboxamide (IB-MECA). In vitro radioligand binding and cAMP assays demonstrated CCPA to be approximately 200- to 400-fold selective for the rabbit A(1)AR and IB-MECA to be approximately 20-fold selective for the rabbit A(3)AR. We observed that (1) pretreatment of rabbits 24 hours earlier with CCPA (100 microgram/kg IV bolus) or IB-MECA (100 or 300 microgram/kg) resulted in an approximately 35% to 40% reduction in the size of the infarct induced by 30 minutes of coronary artery occlusion and 72 hours of reperfusion compared with vehicle-treated rabbits, whereas pretreatment with the selective A(2A)AR agonist CGS 21680 (100 microgram/kg) had no effect; (2) the delayed cardioprotective effect of CCPA, but not that of IB-MECA, was completely blocked by coadministration of the highly selective A(1)AR antagonist N-0861; (3) inhibition of nitric oxide synthase (NOS) with N(omega)-nitro-L-arginine during the 30-minute occlusion abrogated the infarct-sparing action of CCPA but not that of IB-MECA; and (4) inhibition of ATP-sensitive potassium (K(ATP)) channels with sodium 5-hydroxydecanoate during the 30-minute occlusion blocked the cardioprotective effects of both CCPA and IB-MECA. Taken together, these results indicate that activation of either A(1)ARs or A(3)ARs (but not A(2A)ARs) elicits delayed protection against infarction in conscious rabbits and that both A(1)AR- and A(3)AR-induced cardioprotection involves opening of K(ATP) channels. However, A(1)AR-induced late PC uses an NOS-dependent pathway whereas A(3)AR-induced late PC is mediated by an NOS-independent pathway.
Takano
H
H
Division of Cardiology, University of Louisville and Jewish Heart and Lung Institute, Louisville, KY, USA.
Bolli
R
R
Black
R G
RG
Kodani
E
E
Tang
X L
XL
Yang
Z
Z
Bhattacharya
S
S
Auchampach
J A
JA
D000225:Adenine / Q000031:analogs & derivatives / Q000494:pharmacology; D000241:Adenosine / Q000031:analogs & derivatives* / Q000378:metabolism / Q000494:pharmacology; D000818:Animals; D001667:Binding, Competitive / Q000187:drug effects; D002460:Cell Line; D003243:Consciousness; D003652:Decanoic Acids / Q000494:pharmacology; D006801:Humans; D006880:Hydroxy Acids / Q000494:pharmacology; D007457:Iodine Radioisotopes; D019157:Ischemic Preconditioning, Myocardial; D008566:Membranes / Q000378:metabolism; D009203:Myocardial Infarction / Q000378:metabolism / Q000473:pathology / Q000517:prevention & control*; D019335:Nitroarginine / Q000494:pharmacology; D009636:Norbornanes / Q000494:pharmacology; D010627:Phenethylamines / Q000494:pharmacology; D011817:Rabbits; D011869:Radioligand Assay; D043684:Receptor, Adenosine A3; D018047:Receptors, Purinergic P1 / Q000187:drug effects / Q000235:genetics / Q000378:metabolism*
D003652:Decanoic Acids; D006880:Hydroxy Acids; D007457:Iodine Radioisotopes; D009636:Norbornanes; D010627:Phenethylamines; D043684:Receptor, Adenosine A3; D018047:Receptors, Purinergic P1; C061282:2-(4-(2-carboxyethyl)phenethylamino)-5'-N-ethylcarboxamidoadenosine; C073387:N 0861; C084956:N(6)-(3-iodobenzyl)-5'-N-methylcarboxamidoadenosine; D019335:Nitroarginine; C058394:2-chloro-N(6)cyclopentyladenosine; C052853:5-hydroxydecanoic acid; D000225:Adenine; D000241:Adenosine